Cytomegalovirus Serostatus Mismatch in a Kidney Recipient with Prior Treated Infection
A 58-year-old woman with end-stage kidney disease from hypertensive nephrosclerosis has been on hemodialysis for three years and is listed for a deceased-donor kidney transplant. Serologies obtained during evaluation show donor CMV IgG positive and recipient CMV IgG negative. She had a remote history of treated pulmonary tuberculosis completed 20 years ago with no recurrence. Her panel-reactive antibody is 0%, HLA mismatch is 4/6, and she has no history of prior transplants or transfusions. The transplant team is reviewing the perioperative prophylaxis plan and the induction regimen. The patient asks why she needs more medications than a friend who received a transplant at the same center last year. The center's protocol uses rabbit anti-thymocyte globulin for induction in standard-risk patients and a steroid-sparing maintenance regimen with tacrolimus and mycophenolate.
1. Classify this donor-recipient CMV serostatus combination and explain the immunologic and clinical reasoning behind the increased risk. What prophylaxis strategy is most appropriate, and for how long?
Read the worked answer
This is a CMV D+/R− mismatch, the highest-risk serostatus combination for post-transplant CMV disease. The donor is seropositive, meaning latent virus resides in donor-derived leukocytes and tissues; the recipient has no pre-existing CMV-specific memory T cells or neutralizing antibody. After transplant, donor virus can reactivate in the allograft and recipient tissues while the patient is on T-cell–depleting induction (rabbit ATG) and maintenance immunosuppression, blunting primary immune control.
The mismatch is not merely a serologic label: the risk is driven by (1) absence of recipient CMV-specific immunity, (2) intensity of immunosuppression, especially lymphocyte-depleting induction, and (3) viral load exposure from the donor organ. Standard practice is valganciclovir prophylaxis, typically 900 mg daily adjusted for renal function, for 6 months in D+/R− kidney recipients (some centers extend to 6–12 months based on net immunosuppression and institutional data). An alternative is preemptive monitoring with weekly CMV viral load and treatment at a threshold, but prophylaxis is preferred in D+/R− because the risk of severe disease and the reliability of adherence favor prophylaxis. Prophylaxis reduces but does not eliminate risk; late-onset CMV after prophylaxis cessation remains a concern, so surveillance should continue after stopping.
2. The patient develops neutropenia (absolute neutrophil count 900/µL) on valganciclovir at month 3. How would you manage prophylaxis while preserving CMV control, and what alternative agents exist?
Read the worked answer
Valganciclovir-induced myelosuppression is a common and predictable toxicity, especially with mycophenolate and in renal impairment. Management steps: (1) Confirm and grade the neutropenia and exclude other causes (mycophenolate dose, infection, ATG effect, other drugs). (2) Adjust valganciclovir to renal function and consider dose reduction rather than abrupt discontinuation if CMV risk is high, with close CBC monitoring (e.g., twice weekly). (3) Reduce or hold mycophenolate temporarily, since it contributes to marrow suppression. (4) Consider granulocyte colony-stimulating factor if neutropenia is severe or persistent, though it does not treat the underlying drug effect. (5) If valganciclovir must be stopped, switch to preemptive monitoring with frequent CMV viral load and treat if viremia rises; alternatives include foscarnet or cidofovir, but both have significant nephrotoxicity and are generally reserved for ganciclovir-resistant or intolerant cases. (6) CMV immunoglobulin is not standard monotherapy. The key judgment is balancing the risk of CMV disease against the risk of neutropenic sepsis, with a documented monitoring plan and clear thresholds for restarting prophylaxis or treating preemptively.